Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations. (October 2014)

• Record Type: Journal Article
• Authors: Hu, Li-Fen; Gao, Li-Ping; Ye, Ying; Chen, Xi; Zhou, Xiang-Tian; Yang, Hai-Fei; Liiu, Yan-Yan; Mei, Qing; Li, Jia-Bin
• Is Part Of: Journal of chemotherapy. Volume 26:Number 5(2014:Oct.)
• Page Start: 282
• Page End: 286
• Publication Date: 2014-10
• Subjects: Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1179/1973947814Y.0000000168
• Languages: English
• ISSNs: 1120-009X

Abstract

<abstract> <title> <x content-type="archive" xml:space="preserve">Abstract</x> </title> <p>We aimed to investigate the activity levels of several combinations of antimicrobials against <italic>Stenotrophomonas maltophilia</italic>. In this study, the antimicrobial susceptibility of <italic>S. maltophilia</italic> clinical isolates was determined, and the synergistic activity of three pairs of antimicrobial combinations was evaluated by the fractional inhibitory concentration index (FICI). The antimicrobial susceptibility <italic>in vitro</italic> against 83 <italic>S. maltophilia</italic> strains was greater for minocycline (80·7%) than for trimethoprim–sulfamethoxazole (51·8%), and levofloxacin (50·6%). The rate of resistance was highest for ticarcillin–clavulanate and ceftazidime (63·8%) and resistance to trimethoprim–sulfamethoxazole (TMP–SMX) was 48·2%. All three combinations were tested against susceptible isolates. Two of the combinations, TMP–SMX+ceftazidime and levofloxacin+ceftazidime were more effective than the combination of TMP–SMX+levofloxacin. We recommend acquiring more clinical data in order to explore combination therapy, which is a promising treatment of <italic>S. maltophilia</italic> infections. </p> </abstract>